Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary bone lymphoma: a retrospective analysis.

J M Horsman1, J Thomas, R Hough

  • 1YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.

International Journal of Oncology
|May 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.

European journal of cancer (Oxford, England : 1990)·2019
Same author

Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?

European journal of obstetrics, gynecology, and reproductive biology·2019
Same author

Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.

Gynecologic oncology·2018
Same author

Classification systems in Gestational trophoblastic neoplasia - Sentiment or evidenced based?

Cancer treatment reviews·2017
Same author

Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

Gynecologic oncology·2016
Same author

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial.

Journal of bone oncology·2016

This study on primary bone lymphoma found that younger age and complete treatment response are favorable prognostic factors. Combined modality therapy, including chemotherapy, may offer better survival outcomes for patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Primary bone lymphoma is a rare extranodal non-Hodgkin's lymphoma.
  • Understanding its characteristics and treatment is crucial for improving patient outcomes.

Purpose of the Study:

  • To retrospectively define patient and tumor characteristics of primary bone lymphoma.
  • To document management strategies and correlate them with survival.
  • To identify prognostic factors for bone lymphoma.

Main Methods:

  • Retrospective analysis of 37 patients with primary bone lymphoma from the Sheffield Lymphoma Group over 34 years.
  • Documentation of patient demographics, tumor site and histology, and treatment modalities.
  • Correlation of clinical data with survival rates using univariate analysis.

Related Experiment Videos

Main Results:

  • The majority of patients were diagnosed with Grade 2 and diffuse large B-cell lymphoma.
  • Pain and pelvic involvement were common presenting symptoms.
  • Radiotherapy alone or combined with CHOP-like chemotherapy were frequent treatments, yielding a 56.7% overall response rate.
  • 5- and 10-year survival rates were 64.5% and 49.6%, respectively.

Conclusions:

  • Younger age (<60 years) and complete response to treatment are favorable prognostic factors.
  • Combined modality therapy, including CHOP-like chemotherapy, showed a trend towards better survival.
  • Primary bone lymphoma appears to have a better survival rate compared to other extranodal lymphomas.